Simply on the issue of extending the terms of protection that are possible through this agreement as well as CETA, we see it in the European agreement, and we see it locked in effectively within the TPP. I don't think anybody debates the fact that this will lead to an increase in costs of pharmaceuticals. Indeed, I believe the health minister and officials from that department have acknowledged that indeed that's in fact the case.
Rather remarkably the transparency chapter, of all places, includes rules dealing with pharmacare programs. Why you would have an agreement that towards the very end—chapter 26 on transparency—sets out rules for pharmacare programs? It's not clear why it's there. It recognizes that Canada doesn't have that yet, but what it does is lock us into certain rules were we ever to pursue that. Why we would agree at this point in time to programs that may be of import that we haven't even developed yet and say that we're going to allow someone else to establish those rules boggles the mind, quite frankly.